Business
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026, ta
About this update from Immunic, Inc.
[{"type":"text","content":"– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"– CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Receptor Sequences, Underlining Broad-Spectrum Antiviral Effects of Vidofludimus Calcium –","length":159,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026, taking place from February 5-7, in San Diego, California. Both poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Additionally, members of Immunic's management, medical and preclinical teams will be available throughout the event at booth #N9.","length":915,"tagName":"p"},{"type":"text","content":""Together, our two poster presentations at the prestigious ACTRIMS Forum further underscore the unique mechanism of action of vidofludimus calcium and its potential in PMS," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "These latest findings from our phase 2 CALLIPER trial provide additional evidence of vidofludimus calcium's effects on key biological drivers of disease progression, including antiviral immune responses linked to Epstein-Barr virus (EBV) and magnetic resonance imaging (MRI) markers of both acute-focal and chronic-compartmentalized inflammation. The findings further reinforce our belief that vidofludimus calcium has the potential to address underlying mechanisms of disease progression in multiple sclerosis (MS) patients."","length":788,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster Title: Effect o...